AFC
REGN icon

Ares Financial Consulting’s Regeneron Pharmaceuticals REGN Stock Holding History

Ares Financial Consulting’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.3K Sell
71
-5
-7% -$3.4K 0.03% 253
2026
Q1 		$59.1K Buy
76
+49
+181% +$37.5K 0.05% 186
2025
Q4 		$20.9K Buy
+27
New +$18.3K 0.02% 250

Other funds holding REGN

Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
MCI
McDonald Capital Investors Orinda, California $1.37B AUM 1.88% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Ares Financial Consulting's REGN Position: Q2 2026 in Review

Ares Financial Consulting reduced its Regeneron Pharmaceuticals (REGN) stake by 6.6% in Q2 2026, selling an estimated $3.4K and leaving 71 shares worth $44.3K. The position accounts for 0.03% of the portfolio, ranked #253.

Ares Financial Consulting first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. The position peaked at $59.1K in Q1 2026. 635 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Ares Financial Consulting held 71 shares of Regeneron Pharmaceuticals worth $44.3K as of Q2 2026.
  • Ares Financial Consulting sold 5 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.4K.
  • Regeneron Pharmaceuticals made up 0.03% of Ares Financial Consulting's portfolio in Q2 2026, its #253 holding.
  • Ares Financial Consulting first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Ares Financial Consulting's Regeneron Pharmaceuticals position peaked at $59.1K in Q1 2026.
  • 635 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.